Q BioMed’s CEO, Denis Corin describes his company’s answer to Pediatric non-verbal learning disorder, whose signs and symptoms do not match those of any well-described condition and currently does not have a formally accepted diagnosis possibly because difficulties in characterizing this condition remain to this day. Pediatric non-verbal disorder is accompanied with developmental delay, most notably where the toddlers never speak or will start speaking and then regress. Children will often never speak or will start speaking and then regress in this subgroup. Currently, there are no drugs available to ameliorate this condition. As a result, lifetime costs of assisted living and supplemental healthcare average $10 million per person. This is compounded by an additional $10 million during the lifespan of the person due to loss in productivity. Not measuring the severe emotional strain of never talking to your child. This pediatric non-verbal disorder, where children lose or don’t develop speech and manifest with ASD symptoms is rare and limited to approximately 20,000 children a year in the US and about the same in Europe. QBM-001 is given to high-risk genetically identified children during the second year of life to regulate faulty membrane channels that are known to cause migraines and/or seizures. This drug acts as an allosteric regulator of these faulty channels in the brain to potentially alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disability of being non-verbal QBM-001 also reduces inflammation in the brain and by so doing can reduce the amount of long-term nerve loss. For more information on QBM-001, parents are encouraged to visit: http://qbiomed.com/qbm-001-new/
